Brookstone Pharmaceuticals changes its name to Acella Pharmaceuticals

Brookstone Pharmaceuticals, an emerging specialty pharmaceutical company, announced today its decision to change the name of the company to Acella Pharmaceuticals, LLC. This decision has been made to create a company image and brand that more accurately mirrors our commitment to "Accelerating the Health Care Solution" by bringing quality affordable products to customers and patients. Mark Pugh, CEO states, "As we have grown over the last few years, we have evolved into a more integrated pharmaceutical company. We believe this new name, Acella Pharmaceuticals, LLC, better aligns our company's image with our mission of delivering our customers the highest quality product at affordable prices."

The company will continue to operate as a specialty pharmaceutical company bringing value to our customer base while providing savings and choice to patients nationwide. Business contacts will remain unchanged and the company Labeler Code and National Drug Code (NDC) numbers remain unchanged. Our web domain will change to www.AcellaPharma.com.